Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients

INTRODUCTION: Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patients with different ethnic backgrounds. The efficacy and safety of bortezomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, MaoFang, Hou, Jian, Chen, WenMing, Huang, XiaoJun, Liu, ZhuoGang, Zhou, YuHong, Li, Yan, Zhao, Taiyun, Wang, LinNa, Wu, Kwang-Wei, Shen, ZhiXiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209095/
https://www.ncbi.nlm.nih.gov/pubmed/25331616
http://dx.doi.org/10.1007/s12325-014-0159-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209095/
https://www.ncbi.nlm.nih.gov/pubmed/25331616
http://dx.doi.org/10.1007/s12325-014-0159-z

Ejemplares similares